drugset / Trial / NCT02933593

Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

NCT02933593 ↗

RandomizedSingle-groupOpen-labelTreatment

Summary

The investigators plan to monitor the central blood pressure in women with severely elevated blood pressures (160/110) in pregnancy in the acute setting. Currently ACOG recommends 3 different options for blood pressure control, however no one has studied how these medications affect the central pressures, only peripheral blood pressure.

Timeline

Start
2016-08
Primary completion
2017-01
Completion
2017-01

Outcome

Outcome not reported

Stopped: “PI withdrew the protocol”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydralazine Small molecule 5 mg Intravenous
Comparator Hydralazine Small molecule 10 mg Intravenous
Comparator Labetalol Small molecule 20 mg Intravenous
Comparator Labetalol Small molecule 40 mg Intravenous
Comparator Labetalol Small molecule 80 mg Intravenous
Comparator Nifedipine Other / unclassified 10 mg Oral
Comparator Nifedipine Other / unclassified 20 mg Oral

Indications